Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

10.77 -0.14 (-1.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
News headline image
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in September
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.